NASDAQ:ARAV

Aravive (ARAV) Stock Forecast, Price & News

$1.80

+0.04 (+2.27%)

(As of 06/2/2023 ET)

Compare

Today's Range: $1.76
▼
$1.85
50-Day Range: $1.42
▼
$2.29
52-Week Range: $0.58
▼
$2.46

Volume: 454,217 shs
Average Volume: 256,723 shs
Market Capitalization: $107.73 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $8.50

Aravive MarketRank™ Forecast

Analyst Rating: Buy
3.00 Rating Score
Upside/Downside: 411.1% Upside
$9.20 Price Target
Short Interest: Bearish
7.60% of Shares Sold Short
Dividend Strength: N/A
Sustainability: -0.55
Upright™ Environmental Score
News Sentiment: N/A
Insider Trading: N/A
Proj. Earnings Growth: Decreasing
From ($1.26) to ($1.44) Per Share

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.75 out of 5 stars

Medical Sector

776th out of 983 stocks

Pharmaceutical Preparations Industry

390th out of 486 stocks

3.5

Analyst's Opinion

Consensus Rating
Aravive has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 5 buy ratings, no hold ratings, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $9.20, Aravive has a forecasted upside of 411.1% from its current price of $1.80.
Amount of Analyst Coverage
Aravive has only been the subject of 1 research reports in the past 90 days.

0.0

Short Interest

Percentage of Shares Shorted
7.60% of the outstanding shares of Aravive have been sold short.
Short Interest Ratio / Days to Cover
Aravive has a short interest ratio ("days to cover") of 14.8, which indicates bearish sentiment.
Change versus previous month
Short interest in Aravive has recently increased by 5.57%, indicating that investor sentiment is decreasing significantly.

0.0

Dividend Strength

Dividend Yield
Aravive does not currently pay a dividend.
Dividend Growth
Aravive does not have a long track record of dividend growth.

4.7

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
Aravive has received a 75.78% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is driven by its "Clinical research services for cancer" and "Preclinical research services for physical health" products. See details.
Environmental Sustainability
The Environmental Impact score for Aravive is -0.55.

0.6

News and Social Media Coverage

Search Interest
Only 2 people have searched for ARAV on MarketBeat in the last 30 days. This is a decrease of -60% compared to the previous 30 days.
MarketBeat Follows
2 people have added Aravive to their MarketBeat watchlist in the last 30 days.

1.7

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Aravive insiders have not sold or bought any company stock.
Percentage Held by Insiders
60.00% of the stock of Aravive is held by insiders. A high percentage of insider ownership can be a sign of company health.
Percentage Held by Institutions
Only 16.85% of the stock of Aravive is held by institutions.

0.0

Earnings and Valuation

Earnings Growth
Earnings for Aravive are expected to decrease in the coming year, from ($1.26) to ($1.44) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Aravive is -0.80, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Aravive is -0.80, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

See Top Rated MarketRank™ Stocks Here

About Aravive (NASDAQ:ARAV) Stock

Aravive, Inc. operates as a clinical stage biotechnology company, which engages in the development of transformative treatments designed to halt the progression of life threatening disease, including cancer and fibrosis. The company was founded on December 10, 2008 and is headquartered in Houston, TX.

Receive ARAV Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Aravive and its competitors with MarketBeat's FREE daily newsletter.

ARAV Stock News Headlines

May 25, 2023 | finance.yahoo.com

Aravive to Present Promising Updated Data from Phase 2 Trial of Batiraxcept in Combination with Cabozantinib in Clear Cell Renal Cell Carcinoma at ASCO 2023

May 25, 2023 | markets.businessinsider.com

Analysts Offer Insights on Healthcare Companies: Sonnet BioTherapeutics Holdings (SONN), Aravive (ARAV) and Cyclacel Pharmaceuticals (CYCC)

June 2, 2023 | Behind the Markets (Ad)

Laser breakthrough could send stock soaring 2,467%

Laser breakthrough could send stock soaring 2,476% Whenever the military develops a breakthrough technology, timely investors could see groundbreaking returns. General Dynamics returned 8,990%... Boeing soared 4,238%... L3Harris shot up 1,628%...

May 25, 2023 | msn.com

Analyst Expectations for Aravive's Future

May 24, 2023 | msn.com

Aravive: Very Small Company With Late Stage Trial In Ovarian Cancer

May 18, 2023 | markets.businessinsider.com

7 Short-Interest Stocks to Target for Explosive Gains

May 18, 2023 | msn.com

Cantor Fitzgerald Reiterates Aravive (ARAV) Overweight Recommendation

May 17, 2023 | americanbankingnews.com

Q2 2023 Earnings Forecast for Aravive, Inc. (NASDAQ:ARAV) Issued By HC Wainwright

June 2, 2023 | Behind the Markets (Ad)

Laser breakthrough could send stock soaring 2,467%

May 16, 2023 | finance.yahoo.com

Aravive Announces Phase 3 Trial Design for Batiraxcept in Clear Cell Renal Cell Carcinoma

May 16, 2023 | americanbankingnews.com

Aravive, Inc. (NASDAQ:ARAV) to Post Q2 2023 Earnings of ($0.31) Per Share, William Blair Forecasts

May 15, 2023 | finance.yahoo.com

Are Medical Stocks Lagging Boston Scientific (BSX) This Year?

May 12, 2023 | msn.com

EF Hutton Reiterates Aravive (ARAV) Buy Recommendation

May 12, 2023 | finance.yahoo.com

Aravive First Quarter 2023 Earnings: Revenues Beat Expectations, EPS Lags

May 12, 2023 | msn.com

HC Wainwright & Co. Reiterates Aravive (ARAV) Buy Recommendation

May 11, 2023 | msn.com

Unusual Put Option Trade in Aravive (ARAV) Worth $337.50K

May 10, 2023 | msn.com

Recap: Aravive Q1 Earnings

May 10, 2023 | finance.yahoo.com

Aravive Reports First Quarter 2023 Financial Results and Provides Corporate Updates

May 9, 2023 | americanbankingnews.com

Aravive (ARAV) to Release Quarterly Earnings on Wednesday

May 8, 2023 | finance.yahoo.com

Aravive to Host Virtual KOL Event on its Late-Stage Oncology Asset Batiraxcept

April 26, 2023 | finance.yahoo.com

Aravive Announces Poster Presentation on Batiraxcept at 2023 ASCO Annual Meeting

April 17, 2023 | finance.yahoo.com

What Makes Aravive (ARAV) a New Buy Stock

April 11, 2023 | finance.yahoo.com

Aravive Appoints Carolina Petrini as Chief Commercial Officer

April 4, 2023 | markets.businessinsider.com

BTIG Keeps Their Buy Rating on Aravive (ARAV)

March 31, 2023 | americanbankingnews.com

Aravive, Inc. (NASDAQ:ARAV) Short Interest Up 16.0% in March

March 22, 2023 | americanbankingnews.com

William Blair Equities Analysts Raise Earnings Estimates for Aravive, Inc. (NASDAQ:ARAV)

March 21, 2023 | americanbankingnews.com

Aravive, Inc. (NASDAQ:ARAV) Expected to Post Q1 2023 Earnings of ($0.30) Per Share

See More Headlines

ARAV Price History

30 days | 90 days | 365 days | Advanced Chart

ARAV Company Calendar

Last Earnings: 3/15/2023
Today: 6/02/2023
Next Earnings (Estimated): 8/10/2023
Fiscal Year End: 12/31/2023

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Pharmaceutical preparations
Sub-Industry: N/A
Sector: Medical
Current Symbol: NASDAQ:ARAV
CUSIP: N/A
CIK: 1513818
Web: www.aravive.com
Phone: (936) 355-1910
Fax: N/A
Employees: 17
Year Founded: N/A

Price Target and Rating

Average Stock Price Forecast: $9.20
High Stock Price Forecast: $12.00
Low Stock Price Forecast: $2.00
Forecasted Upside/Downside: +380.2%
Consensus Rating: Buy
Rating Score (0-4): 3.00
Research Coverage: 5 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($2.24)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-76,320,000.00
Net Margins: -1,187.30%
Pretax Margin: -1,187.30%
Return on Equity: -1,865.78%
Return on Assets: -157.42%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 1.93
Quick Ratio: 1.93

Sales & Book Value

Annual Sales: $9.14 million
Price / Sales: 11.59
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: ($0.65) per share
Price / Book: -2.72

Miscellaneous

Outstanding Shares: 59,850,000
Free Float: 23,938,000
Market Cap: $105.93 million
Optionable: Optionable
Beta: 2.35

Key Executives

Gail Frances McIntyre
President, Chief Executive Officer & Director

Leonard Scott Dove
Chief Operating Officer

Rudy C. Howard
Chief Financial & Accounting Officer

Robert B. Geller
Chief Medical Officer

Maria Carolina Petrini
Chief Commercial Officer

Key Competitors

View All Competitors

Institutional Ownership

View All Institutional Transactions

ARAV Stock - Frequently Asked Questions

Should I buy or sell Aravive stock right now?: 5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Aravive in the last twelve months. There are currently 5 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" ARAV shares.
View ARAV analyst ratings or view top-rated stocks.
What is Aravive's stock price forecast for 2023?: 5 equities research analysts have issued 12-month target prices for Aravive's shares. Their ARAV share price forecasts range from $2.00 to $12.00. On average, they anticipate the company's share price to reach $9.20 in the next year. This suggests a possible upside of 419.8% from the stock's current price.
View analysts price targets for ARAV or view top-rated stocks among Wall Street analysts.
How have ARAV shares performed in 2023?: Aravive's stock was trading at $1.32 at the start of the year. Since then, ARAV stock has increased by 34.1% and is now trading at $1.77.
View the best growth stocks for 2023 here.
When is Aravive's next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Thursday, August 10th 2023.
View our ARAV earnings forecast.
How were Aravive's earnings last quarter?: Aravive, Inc. (NASDAQ:ARAV) released its earnings results on Wednesday, March, 15th. The company reported ($0.46) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.33) by $0.13. The company earned $1.47 million during the quarter, compared to analysts' expectations of $0.37 million. Aravive had a negative net margin of 1,187.30% and a negative trailing twelve-month return on equity of 1,865.78%.
What other stocks do shareholders of Aravive own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Aravive investors own include Sorrento Therapeutics (SRNE), Dynavax Technologies (DVAX), SCYNEXIS (SCYX), VBI Vaccines (VBIV), Applied Genetic Technologies (AGTC), Flexion Therapeutics (FLXN), Inovio Pharmaceuticals (INO), T2 Biosystems (TTOO), Arbutus Biopharma (ABUS) and BioCryst Pharmaceuticals (BCRX).

What is Aravive's stock symbol?: Aravive trades on the NASDAQ under the ticker symbol "ARAV."
Who are Aravive's major shareholders?: Aravive's stock is owned by a number of retail and institutional investors. Top institutional shareholders include Geode Capital Management LLC (0.36%), BlackRock Inc. (0.35%), Assenagon Asset Management S.A. (0.33%), Two Sigma Advisers LP (0.27%), Renaissance Technologies LLC (0.26%) and Jane Street Group LLC (0.11%). Insiders that own company stock include Amato Giaccia, Gail Frances Mcintyre and Vinay Shah.
View institutional ownership trends.
How do I buy shares of Aravive?: Shares of ARAV stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.
What is Aravive's stock price today?: One share of ARAV stock can currently be purchased for approximately $1.77.
How much money does Aravive make?: Aravive (NASDAQ:ARAV) has a market capitalization of $105.93 million and generates $9.14 million in revenue each year. The company earns $-76,320,000.00 in net income (profit) each year or ($2.24) on an earnings per share basis.
How can I contact Aravive?: Aravive's mailing address is River Oaks Tower 3730 Kirby Drive Suite 1200, Houston TX, 77098. The official website for the company is www.aravive.com. The company can be reached via phone at (936) 355-1910 or via email at christina@sternir.com.

This page (NASDAQ:ARAV) was last updated on 6/2/2023 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial